Pyxis Oncology Discloses Inducement Grants According to Nasdaq Rule

Boston, June 28, 2024 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. PYXS, a clinical-stage biotechnology firm engaged in the creation of advanced cancer treatments, has publicly announced inducement grants sanctioned by the Compensation Committee of its Board of Directors. With a mission to revolutionize therapy for challenging cancers, PYXS specializes in the research and development of antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs). Operating from its headquarters in Cambridge, Massachusetts, PYXS aspires to make strides in oncology by targeting tumors with precision medicine.

Commitment to Innovation in Cancer Therapy

The cutting-edge work conducted at PYXS represents a beacon of hope in the struggle against some of the most persistent and resistant forms of cancer. By focusing on next-generation therapeutics, PYXS aims to bridge the gap where traditional cancer treatments have fallen short. The inducement grants are a strategic move to incentivize and retain top talent, essential for driving forward the company's ambitious research endeavors.

Strategic Grants to Foster Growth

In alignment with Nasdaq Listing Rule 5635(c)(4), the inducement grants serve as a testament to PYXS's dedication to comply with regulatory guidelines while also promoting a productive and innovative corporate culture. As PYXS continues to navigate the complex landscape of cancer drug development, these grants reflect the company's proactive stance in fostering a workforce committed to achieving remarkable breakthroughs in oncology.

Pyxis, Oncology, Inducement